Active substance autologous anti-CD19 CD3+ cells (CAR+ viable T cells)
Holder     Gilead Sciences Belgium bv
Status Running
Indication treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor
Public documents Approbation
  Information for the patient
  Informed consent
Last update



Last updated on 28/09/2022